Clinical Trial Update: Follow-up to Welcome Study C87042 [NCT00308581] Examining Certolizumab Pegol (CDP870) in Subjects With Crohn's Disease [Phase 3]

View source ↗

Summary

Phase 3 follow-up study of certolizumab pegol (CDP870) in Crohn's disease completed with posted results.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Crohn Disease

Drugs mentioned

• Certolizumab pegol (certolizumab pegol)

Snippet

Sponsor: UCB Pharma | Conditions: Crohn's Disease | Phase 3 | Status: COMPLETED | Results posted: 2011-07-12